点击上方的 行舟Drug ▲ 添加关注 中国获批上市 2019年2月26日,礼来制药的GLP-1受体激动剂(RA)周制剂度易达®(度拉糖肽)(Dulaglutide)正式获得国家药品监督管理局(NMPA)批准进入中国,适用于成人2型糖尿病患者的血糖控制,包括单药以及接受二甲双胍和/或磺脲类药物治疗血糖仍控制不佳的患者。 以中国患者人群为主...
1) 与SGLT-2i或GLP-1RA相比,DPP-4i缺乏益处; 2) 与SGLT-2i或GLP-1RA相比,DPP-4i可能会增加 CHF 引起的住院率等。 温馨提示: 药物的适用性应基于我国国情来判断。当前我国多部共识建议[5-7]: 1) 对于有MET有禁忌证或无法耐受的...
GLP-1受体激动剂(GLP-1RA)在降糖的同时更能带来明确的心血管获益,即主要心血管不良事件发生风险显著降低,引领了糖尿病管理从血糖管理到整体化管理的治疗理念改变,更成为国内外指南一致推荐的ASCVD合并2型糖尿病(T2DM)全程治疗的一线药物。 为进一步探讨GLP-1 RA在临床中的应用,“第二届诺和诺德心血管代谢峰会”(NNC...
4月6日,华西医院内分泌代谢科李舍予等联合国内外多名学者发表在BMJ上的一项系统综述和网络Meta分析表明,在13类治疗糖尿病的药物中,除了钠葡萄糖共转运蛋白2抑制剂(SGLT2i)和胰高血糖素样肽1受体激动剂(GLP-1 RA)有明确的心肾益处外,非甾体盐皮质激素受体拮抗剂(MRA)非奈利酮也有类似的获益。 分析显示,SGLT2i...
(2) the aggressive prosecution of bad actors who are illegally trafficking counterfeit or adulterated GLP-1 RA products, and (3) an independent task force outside of the FDA be charged with the final determination for adding or removing a drug from the “drug shortages” list wi...
●Food and Drug Administration (FDA):美国食品药品监督管理局 ●European Medicines Agency (EMA):欧洲药品管理局 02 药政事务与合规 Regulatory Affairs and Compliance ●Regulatory Affairs (RA):药政事务 ●Market Authorization (MA):上市许可 ●post-appro...
(2) the aggressive prosecution of bad actors who are illegally trafficking counterfeit or adulterated GLP-1 RA products, and (3) an independent task force outside of the FDA be charged with the final determination for adding or removing a drug from the “drug shortages” list w...
GLP-1 Receptor Agonist Market, By Drug Class (Exenatide, Liraglutide, Dulaglutide, Lixisenatide, Albiglutide, Semaglutide), By Route of Administration (Parenteral and Oral), By Application (Type 2 Diabetes Mellitus, Obesity, Liver Cirrhosis, Non-alcoholic Steatohepatitis, Others), By Distribution ...
26.一种治疗患有代谢性疾病的受试者的方法,所述方法包括向所述受试者递送重组腺相关病毒(rAAV),所述rAAV具有来自腺相关病毒rh91的AAV衣壳和包装在所述AAV衣壳中的载体基因组,所述载体基因组包括AAV反向末端重复序列(ITR)、编码包括GLP-1类似物和人IgG4 Fc的融合蛋白的序列以及指导所述融合蛋白的表达的调控...
This drug also produces significant weight decrement. Mean baseline body weight was 91–93 kg which was significantly decreased by 3.73 kg with 0.5 mg, 4.53 kg with 1 mg, and non-significantly decreased in placebo with only 0.98 kg. The most important reported side effects...